Open Monoclonal Technology, Inc. Company Profile
Open Monoclonal Technology, Inc. (“OMT”) is a private biotechnology company with a new, fully human monoclonal antibody platform based on transgenic rats. The rat is a widely used laboratory animal with a well characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies. OMT’s antibody platform results from an improved understanding of B-cell development and a novel approach to the inactivation of endogenous antibody expression. OMT is financed by Essex Woodlands Health Ventures.
News Articles
[Open Monoclonal Technology] uses its {OmniRat} technology for [J&J]'s [CNA Development]
[Open Monoclonal Technology Inc.] (therapeutic antibodies) will use its {OmniRat} platform to make antibodies with fully human idiotypes for [CAN Development LLC], an affiliate of [Johnson & Johnson]â...
WuXi partners with Open Monoclonal to develop antibody drugs
WuXi PharmaTech signed a deal with Open Monoclonal Technology to develop antibody drug candidates using the latter's OmniRat -More-
Pfizer in a licensing deal with Open Monoclonal Technology
Open Monoclonal Technology announced an agreement whereby Pfizer will use OMT’s OmniRat for antibody research and development. OmniRat is a platform technology that generates fully human antibodies...
Open Monoclonal, WuXi Pharma to develop therapeutic antibody candidates
WuXi PharmaTech and Open Monoclonal Technology (OMT) have entered into an agreement to use OMT's OmniRat to develop therapeutic antibody candidates for commercialization by WuXi's global customers.
OMT Announces New Antibody Discovery Program
Open Monoclonal Technology, Inc. (OMT) today announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will u...
Open Monoclonal Technology, Inc. (OMT) today announced a discovery collaboration with CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. OMT will e...
Open Monoclonal Technology Announces OmniRat™ Antibody License to Pfizer
Open Monoclonal Technology, Inc. (OMT), a provider of human therapeutic antibody technologies, today announced an agreement whereby Pfizer Inc., a global pharmaceutical company, w...
Drugs and Medications
Synagis
BEXXAR (Tositumomab and Iodine I 131 Tositumomab)
Hemofil m [Baxter Healthcare Corporation]
HEMOFIL M Antihemophilic Factor (Human)Method M, Monoclonal Purified
Heartburn relief to go [Breakthrough Products Inc.]
Urgent-Rx Heartburn Relief to Go
These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. ARZERRA (ofatumumab)Injection, for intravenous infusion...
PubMed Articles
Abstract Background: Detection and quantification of monoclonal proteins is hampered when the monoclonal peak coincides with one of the regular bands in serum proteinelectrophoresis. The objective o...
Introduction: The number of monoclonal antibodies available for clinical use and under development has dramatically increased in the last 10 years. Understanding their pharmacokinetics and pharmacodyn...
Monoclonal antibodies are the most important family of biopharmaceutical compounds in terms of market share. At present, 30 monoclonal antibodies have been approved and are now commercialized for ther...
Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies.
Since the advent of hybridoma technology 35 years ago, research on monoclonal antibodies has developed enormously. Monoclonal antibodies of mouse origin were the first to be produced and continue to b...
Clinical Trials
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding the...
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the...
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Col...
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the...
Monoclonal Antibody Therapy in Treating Patients With Brain Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study t...
Companies
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. (“OMT”) is a private biotechnology company with a new, fully human monoclonal antibody platform based on transgenic rats. The rat is a w...
Open eHealth Foundation (OeHF), launched at HIMSS 08, uses existing open source projects for developing a platform on which its members and other providers can create open source components that a...
Open Source Initiative (OSI) is a non-profit corporation dedicated to managing and promoting the Open Source Definition for the good of the community, specifically through the OSI Certified Open Sourc...
Open Health Tools is a nonprofit organization that promotes the availability of open technologies in healthcare worldwide. With over 60 members, OHT is transforming the global mar...
Monoclonal antibody technology was the research breakthrough of the 1980’s. With the discovery by Milstein and Kohler in Cambridge, England, Hybritech became the first company dedicated to the produ...
More Information about "Open Monoclonal Technology, Inc." on BioPortfolio
We have published hundreds of Open Monoclonal Technology, Inc. news stories on BioPortfolio along with dozens of Open Monoclonal Technology, Inc. Clinical Trials and PubMed Articles about Open Monoclonal Technology, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Open Monoclonal Technology, Inc. Companies in our database. You can also find out about relevant Open Monoclonal Technology, Inc. Drugs and Medications on this site too.
